“…The haploid progeny, which is typically sterile, are then screened for CRISPR–Cas-induced mutations ( Figure 4B ) and subsequently treated with a colchicine mitotic inhibitor ( Prasanna et al, 2012 ; Melchinger et al, 2016 ; Chaikam et al, 2019 ) or another less toxic doubling agent ( Geiger and Gordillo, 2009 ; Häntzschel and Weber, 2010 ) to produce fertile doubled haploid and gene-edited nontransgenic plants ( Kelliher et al, 2019 ; Wang et al, 2019 ; Figures 4C – E ). However, improvements are needed to overcome the inherent problems related to haploid induction per se ( Trentin et al, 2020 ; Jacquier et al, 2021 ). For example, CRISPR-Cas can be used before or in parallel to HI-Edit to: (1) increase the haploid induction rates by targeting genes related to high haploid induction ( Kelliher et al, 2017 ; Zhong et al, 2019 ) or genes related to the inducer exclusion ( Kelliher et al, 2019 ); (2) accelerate and accurately sort kernels/seedlings with haploid embryos from normal embryos by modifying visual traits such as anthocyanin ( Chaikam et al, 2019 ) or by integrating visible transgenic markers into the inducers ( Yu and Birchler, 2016 ; Xu et al, 2021 ; Yan et al, 2021 ) or even targeting genes involved in the oil content of seeds ( Melchinger et al, 2013 ) and fixing recessive alleles of morphological traits in donors ( Trentin et al, 2020 ).…”